Types of Research
- (-) Remove Market & Value Chain Analysis filter Market & Value Chain Analysis
- (-) Remove Literature Review filter Literature Review
- (-) Remove Research & Development filter Research & Development
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
- (-) Remove South Asia Region and Selected Countries filter South Asia Region and Selected Countries
- (-) Remove Global filter Global
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
This research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. We summarize the public good characteristics of R&D for agriculture in general and for commodity and subsistence crops in particular, as well as R&D for health in general and for neglected diseases in particular, with a focus on Sub-Saharan Africa and South Asia. Finally, we present rationales for which funders are predicted to fund which R&D types based on these funder and R&D characteristics. We then compile available statistics on funding for agricultural and health R&D from private, public and philanthropic sources, and compare trends in funding from these sources against expectations. We find private agricultural R&D spending focuses on commodity crops (as expected). However contrary to expectations we find public and philanthropic spending also goes largely towards these same crops rather than staples not targeted by private funds. For health R&D private funders similarly concentrate on diseases with higher potential financial returns. However unlike in agricultural R&D, in health R&D we observe some specialization across funders – especially for neglected diseases R&D - consistent with funders’ expected relative advantages.
The concept of global public goods represents a framework for organizing and financing international cooperation in global health research and development (R&D). Advances in scientific and clinical knowledge produced by biomedical R&D can be considered public goods insofar as they can be used repeatedly (non-rival consumption) and it is difficult or costly to exclude non-payers from gaining access (non-excludable). This paper considers the public good characteristics of biomedical R&D in global health and describes the theoretical and observed factors in the allocation R&D funding by public, private, and philanthropic sources.
This brief reviews the various definitions of global public goods (GPGs) and regional public goods (RPGs) found in the literature and provides examples of each in six frequently discussed sectors: environment, health, knowledge, security, governance, and infrastructure. We identify multiple alternative definitions that have gained some traction in the literature, but GPGs are generally agreed to exhibit publicness in consumption, distribution of benefits, and decision-making. Because policy choices determine what is and what is not a GPG, there cannot be a fixed list of such goods; some always have the property of global publicness, while others have over time changed from being local or national to being global in terms of benefits and costs. GPGs are thus redefined as goods that are in the global public domain. GPG and RPG financing mechanisms include payments by users and beneficiaries, taxes, fees, and levies, private funding by non-profit corporations, profit-making firms, and philanthropic individuals and organizations, national and international public resources, and partnerships between several sources of financing. We conclude with an analysis of trends in GPG and RPG financing through Official Development Assistance (ODA) using time series data from the OECD’s Creditor Reporting System and other sources. We find that 14% of ODA in 2014 was allocated to sub-sectors labelled by Reiner et al. as GPGs, while 15% of ODA was allocated to RPGs, and that GPG and RPG spending has steadily increased from 2002-2014.
Cereal yield variability is influenced by initial conditions such as suitability of the farming system for cereal cultivation, current production quantities and yields, and zone-specific potential yields limited by water availability. However, exogenous factors such as national policies, climate, and international market conditions also impact farm-level yields directly or provide incentives or disincentives for farmers to intensify production. We conduct a selective literature review of policy-related drivers of maize yields in Ethiopia, Kenya, Malawi, Rwanda, Tanzania, and Uganda and pair the findings with FAOSTAT data on yield and productivity. This report presents our cumulative findings along with contextual evidence of the hypothesized drivers behind maize yield trends over the past 20 years for the focus countries.
The review consists of a summary of the emergence of agribusiness clusters, SEZs and incubators since 1965 (with a focus on smallholder agriculture-based economies in Latin America, Africa, and Asia), followed by a series of brief case studies of example programs with particular relevance for guiding proposed clusters/incubators in the countries of Ethiopia, Tanzania, Nigeria and the Eastern Indian states of Uttar Pradesh, Bihar, and Odisha. Summary conclusions draw upon published reports and primary analysis of case studies to highlight apparent determinants of success and failure in agribusiness investment clusters and incubators, including characteristics of the business environment (markets, policies) and characteristics of the organizational structure (clusters, accelerators) associated with positive smallholder outcomes.
This report provides a genderal overview of the sweet potato value chain in Ethiopia. The first section describes trends in sweet potato production and consumption since the early 1990s. The second section describes the uses and importance of sweet potatoes in Ethiopia. The final section discuss major issues in production, post-production, and marketing. The literature available on sweet potetoes in Ethiopia was quite limited and draws on the wider literature on sweet potatoes in East Africa where needed. We find that Ethiopia ranks fifteenth in the world in terms of sweet potato production. Production has been rising quickly since 2008, following a period of slow decline in the early 2000s. Yields have also been rising slowly since 2008, but are below their peak from 2001. Sweet potato roots are consumed domestically, mostly by poor rural households. The vines also provide an important source of feed for livestock during the dry season. Major constraints to sweet potato production in Ethiopia include a lack of quality planting materials, pests and disease, and underdeveloped markets.
Uganda is the biggest sweet potato producer in Africa in terms of area harvested and production, although Burundi, Rwanda and Madagascar have significantly higher yields. Sweet potato is a major crop in Uganda, ranking third in cultivated area following plantains and cassava. Sweet potato ranks fourth in gross agricultural production value. The Government of Uganda has recognized sweet potatoes as an important crop for the country and a research priority, especially through establishing the National Agricultural Research Organization potato center. This report provides a general overview of the sweet potato value chain in Uganda. The first section describes trends in sweet potato production and consumption since 1996. The second section describes the varieties grown and their uses. The final section summarizes current practices and constraints in production, processing, and marketing.
This report provides a general overview of the sweet potato value chain in Tanzania. The first section describes trends in sweet potato production and consumption since 1990. The second section describes the uses and importance of sweet potatoes in Tanzania. The final section outlines current practices and constraints in production, post-production, and marketing. Tanzania ranks fifth in the world in quantity of sweet potatoes produced. Production and consumption of sweet potatoes have been relatively constant over the past 10 years, although both production and consumption in this period have been high in comparison to earlier decades. We find that sweet potato yields increased in the early 2000s, but have stagnated since, and are far short of potential yields. Sweet potato consumption is almost entirely domestic and plays an important role in nutrition and food security for smallholder farmers. Sweet potato production faces a variety of constraints, including pests and disease, short shelf life, lack of planting materials, damage during handling, and lack of market access.